12,193 results match your criteria Nephritis Lupus

Correspondence on "Update on the diagnosis and management of systemic lupus erythematosus" by Fanouriakis .

Ann Rheum Dis 2021 Aug 3. Epub 2021 Aug 3.

Department of Rheumatology and Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

View Article and Full-Text PDF

Coincidental light chain induced proximal tubulopathy with lupus nephritis: a case report and review of the literature.

J Med Case Rep 2021 Aug 4;15(1):388. Epub 2021 Aug 4.

Department of Pathology and Laboratory Medicine, College of Medicine, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.

Background: We report a case of light chain proximal tubulopathy associated with lupus nephritis in a patient known to have systemic lupus erythematosus. The kidney can be injured in several ways in any of these disorders. Light chain proximal tubulopathy is a rare form of renal tubular injury that may occur in and complicate plasma cell dyscrasia, characterized by cytoplasmic inclusions of the monoclonal light chain within proximal tubular cells. Read More

View Article and Full-Text PDF

Positron emission tomography and single photon emission computed tomography imaging of tertiary lymphoid structures during the development of lupus nephritis.

Int J Immunopathol Pharmacol 2021 Jan-Dec;35:20587384211033683

RNA and Molecular Pathology Research Group, Institute of Medical Biology, Faculty of Health Sciences, 8016UiT The Arctic University of Norway, Tromsø, Norway.

Lymphoid neogenesis occurs in tissues targeted by chronic inflammatory processes, such as infection and autoimmunity. In systemic lupus erythematosus (SLE), such structures develop within the kidneys of lupus-prone mice ((NZBXNZW)F1) and are observed in kidney biopsies taken from SLE patients with lupus nephritis (LN). The purpose of this prospective longitudinal animal study was to detect early kidney changes and tertiary lymphoid structures (TLS) using in vivo imaging. Read More

View Article and Full-Text PDF

YAP1 Overexpression Is Associated with Kidney Dysfunction in Lupus Nephritis.

Pathobiology 2021 Aug 3:1-12. Epub 2021 Aug 3.

Department of Pathophysiology, Guizhou Medical University, Guiyang, China.

Objective: The goal of the present study was to determine the expression of yes-associated protein 1 (YAP1) in renal tissues of mice with lupus nephritis (LN) and elucidate its role in the progression of renal fibrosis.

Methods: C57BL/6 mice and MRL/lpr mice were selected for experimental comparison. Mouse kidney tissues were removed and sectioned for hematoxylin and eosin staining, Masson's trichome staining, Sirius staining, and immunohistochemistry. Read More

View Article and Full-Text PDF

Cluster of highly expressed interferon-stimulated genes associate more with African ancestry than disease activity in patients with systemic lupus erythematosus. A systematic review of cross-sectional studies.: Expression of interferon stimulated genes in systemic lupus.

Transl Res 2021 Jul 31. Epub 2021 Jul 31.

Copenhagen Lupus and Vasculitis Clinic, Rigshospitalet, Copenhagen University Hospital, Denmark. Electronic address:

Type I interferons (IFN) are central players in the pathogenesis of systemic lupus erythematosus (SLE) and the up-regulation of interferon-stimulated genes (ISGs) in SLE patients is subjected to increasing scrutiny as for its use in diagnosis, stratification and monitoring SLE patients. Determinants of this immunological phenomenon are yet to be fully charted. The purpose of this systematic review was to characterize expressions of ISGs in blood of SLE patients and to analyze if they associated with core demographic and clinical features of SLE. Read More

View Article and Full-Text PDF

Lupus Nephritis with Obvious IgA deposits in the Kidneys.

Am J Med Sci 2021 Jul 29. Epub 2021 Jul 29.

Department of Nephrology, Peking University International Hospital, Beijing 102206, PR. China. Electronic address:

Objective: The purpose of the current study was to describe the clinico-pathological characteristics and outcomes in patients with lupus nephritis with IgA deposits in the kidneys.

Materials And Methods: A total of 258 patients with lupus nephritis with complete clinical data and follow-up was enrolled. They were divided into two groups: the IgA deposits group and the non-IgA deposits group. Read More

View Article and Full-Text PDF

The Use of Curcumin for the Treatment of Renal Disorders: A Systematic Review of Randomized Controlled Trials.

Adv Exp Med Biol 2021 ;1291:327-343

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Chronic kidney disease (CKD) is one of the significant causes of morbidity and mortality worldwide, which could develop and progress to end-stage renal disease. Increased inflammation and reduced antioxidant capacity commonly occur in CKD and hemodialysis patients. Curcumin is a natural bioactive compound with antioxidant and anti-inflammatory properties. Read More

View Article and Full-Text PDF

An unusual presentation to the burn' unit - a cautionary tale.

J Burn Care Res 2021 Jul 29. Epub 2021 Jul 29.

Reconstructive Surgery and Regenerative Medicine Research Group, Institute of Life Sciences, Swansea University Medical School, Swansea.

We report a case of a 34-year old female with systemic lupus erythematosus (SLE) and lupus nephritis who was referred to the regional burns service with a suspected contact burn to the left flank and hypogastrium from a hot water bottle. The patient had been applying a hot-water bottle to the area at night for pain relief and after 3-days she noticed a localised area of erythema which became larger and began to blister over a period of 5-days. The blistered areas were erythematous and wet, however the capillary refill time was sluggish. Read More

View Article and Full-Text PDF

Is Mean Platelet Volume Related to Disease Activity in Systemic Lupus Erythematosus?

Int J Clin Pract 2021 Jul 29:e14676. Epub 2021 Jul 29.

Department of Hematology, Lokman Hekim hospital, Ankara, Turkey.

Systemic lupus erythematosus (SLE) is a connective tissue disease that is chronic, recurrent, and multisystem with unknown etiology. There is still no single biomarker that is pathognomonic for the disease. We know that platelets are the main part of hemostasis and thrombosis. Read More

View Article and Full-Text PDF

An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis.

Drug Deliv Transl Res 2021 Jul 28. Epub 2021 Jul 28.

Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.

Studies have suggested imatinib mesylate (ImM) as a potential treatment for systemic lupus erythematosus nephritis (SLEN). However, ImM has limited renal excretion. The goal of the current research was to develop an ImM containing nanoformulation, conduct studies to evaluate pharmacokinetics, and determine whether kidney deposition can be enhanced in a mouse model of SLEN. Read More

View Article and Full-Text PDF

Disseminated Herpes Zoster on a Child with Systemic Lupus Erythematosus and Lupus Nephritis.

Infect Drug Resist 2021 20;14:2777-2785. Epub 2021 Jul 20.

Department of Dermatology and Venereology, Faculty of Medicine, Universitas Brawijaya/ Dr. Saiful Anwar Regional Hospital, Malang, Indonesia.

Introduction: Disseminated herpes zoster (DHZ) is a complication of herpes zoster (HZ) associated with an immunocompromised state. Immunocompromised conditions in systemic lupus erythematosus (SLE) and lupus nephritis increase the incidence of DHZ.

Case: A 14-year-old girl was consulted with a complaint of painful reddish blisters for the previous 4 days. Read More

View Article and Full-Text PDF

Is combination of immunosuppressive drugs the answer to reduce glucocorticoid burden in patients with lupus nephritis?

Clin Rheumatol 2021 Jul 28. Epub 2021 Jul 28.

Department of Clinical Immunology and Rheumatology, Sardar Vallabhbhai Patel Institute of Medical Sciences and Research and Smt. NHL Municipal Medical College, Ahmedabad, 380006, Gujarat, India.

View Article and Full-Text PDF

Rituximab use in pediatric systemic lupus erythematosus: Indications, efficacy and safety in an Indian cohort.

Lupus 2021 Jul 27:9612033211034567. Epub 2021 Jul 27.

Division of Pediatric Rheumatology, 28928Sir Ganga Ram Hospital, Institute of Child Health, Sir Ganga Ram Hospital, New Delhi, India.

Children with systemic lupus erythematosus have a more challenging and difficult course as compared to their adult counterparts. Today, the aim of therapy for any child with lupus is to keep the child in a state of sustained remission with minimal or no use of steroids. This laudable goal is often difficult to achieve for the child with lupus. Read More

View Article and Full-Text PDF

Cf-02, a novel benzamide-linked small molecule, blunts NF-κB activation and NLRP3 inflammasome assembly and improves acute onset of accelerated and severe lupus nephritis in mice.

FASEB J 2021 08;35(8):e21785

Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.

In the present study, acute onset of severe lupus nephritis was successfully treated in mice using a new, benzamide-linked, small molecule that targets immune modulation and the NLRP3 inflammasome. Specifically, 6-(2,4-difluorophenyl)-3-(3-(trifluoromethyl)phenyl)-2H-benzo[e][1,3]oxazine-2,4(3H)-dione (Cf-02) (a) reduced serum levels of IgG anti-dsDNA, IL-1β, IL-6, and TNF-α, (b) inhibited activation of dendritic cells and differentially regulated T cell functions, and (c) suppressed the NF-κB/NLRP3 inflammasome axis, targeting priming and activating signals of the inflammasome. Moreover, treatment with Cf-02 significantly inhibited secretion of IL-1β in lipopolysaccharide-stimulated macrophages, but this effect was abolished by autophagy induction. Read More

View Article and Full-Text PDF

Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity.

Kidney Int Rep 2021 Jul 28;6(7):1949-1960. Epub 2021 Apr 28.

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Introduction: Lupus nephritis (LN) confers a poor prognosis, mainly from lack of effective laboratory tests to diagnose and to evaluate therapies. We have previously shown that a set of 6 urinary biomarkers (NGAL, KIM-1, MCP-1, adiponectin, hemopexin, and ceruloplasmin) are highly sensitive and specific to identify adult and pediatric patients with active LN using renal biopsy as reference standard. Using these combinatorial urinary biomarkers, the Renal Activity Score for Lupus (RAIL) score was established, with biomarkers measured by enzyme-linked immunosorbent assay (ELISA). Read More

View Article and Full-Text PDF

Predictors of adverse pregnancy outcome in a cohort of women with systemic lupus erythematosus in Malaysia.

S G Ong H J Ding

Med J Malaysia 2021 Jul;76(4):466-473

Kuala Lumpur Hospital, Department of Medicine, Rheumatology Unit, Jalan Pahang, 50586 Kuala Lumpur, Malaysia.

Introduction: Pregnancy in women with systemic lupus erythematosus (SLE) is known to be associated with adverse pregnancy outcomes (APO). We aimed to determine the frequency of APO, the associated variables and predictors.

Materials And Methods: This retrospective study included all pregnancies seen at the SLE Clinic, Kuala Lumpur Hospital from January 2008 to May 2020. Read More

View Article and Full-Text PDF

Treatment outcomes in refractory lupus nephritis: Data from an observational study.

Lupus 2021 Jul 26:9612033211033980. Epub 2021 Jul 26.

Department of Clinical Immunology and Rheumatology, Nizam's Institute of Medical Sciences, Hyderabad, India.

Objectives: Despite current advances in treatment, refractory lupus nephritis (RLN) continues to pose a challenge. The present paper studies the clinical profile and treatment outcomes in patients with RLN.

Methods: This observational, bidirectional study enrolled consecutive lupus nephritis (LN) patients from August 2018 to January 2019, who either failed to improve within three months, did not achieve partial renal response (PR) at six months, or did not achieve complete renal response (CR) after two years of treatment. Read More

View Article and Full-Text PDF

Immunopathological analysis of the expression of glomerular exostosin 1 and exostosin 2 in Japanese patients with lupus nephritis.

Virchows Arch 2021 Jul 24. Epub 2021 Jul 24.

Department of Medicine, Division of Nephrology, Showa University School of Medicine, Tokyo, Japan.

Exostosin 1 and exostosin 2 (EXT1/EXT2) on glomerular basement membrane (GBM) were recently reported as novel putative antigens in secondary membranous nephropathy with autoimmune disease. However, the clinical significance of glomerular EXT1/EXT2 remains elusive in patients with lupus nephritis (LN). The immunofluorescence staining pattern of glomerular EXT1/EXT2 is also undetermined in membranous LN (MLN) or proliferative LN (PLN). Read More

View Article and Full-Text PDF

Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR).

Lupus Sci Med 2021 Jul;8(1)

The Kellgren Centre for Rheumatology, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK

Objective: To quantify how well phase III randomised clinical trials in both SLE and lupus nephritis (LN) represents a real-world SLE cohort.

Methods: Literature reviews were performed of major published phase III SLE (n=12) and LN (n=6) clinical trials (ClinicalTrials.gov). Read More

View Article and Full-Text PDF

Elevation of serum fibroblast growth factor 23 level in a pediatric patient with lupus nephritis.

CEN Case Rep 2021 Jul 22. Epub 2021 Jul 22.

Department of Endocrinology, Chiba Children's Hospital, 579-1 Hetacho, Midori-ku, Chiba, Chiba, 266-0007, Japan.

Fibroblast growth factor 23 (FGF-23), a hormone mainly secreted by osteocytes and osteoblasts, regulates phosphate and vitamin D levels. However, the in vivo significance of FGF-23 is not fully elucidated. This case report describes a 12-year-old girl with systemic lupus erythematosus (SLE), lupus nephritis, and an elevated serum FGF-23 level. Read More

View Article and Full-Text PDF

Autoantibody Profile of Egyptian Juvenile Systemic Lupus Erythematosus Patients and Its Association with Clinical Characteristics and Disease Activity.

Open Access Rheumatol 2021 16;13:201-212. Epub 2021 Jul 16.

Internal Medicine Department, Division of Rheumatology and Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Objective: This study was conducted to estimate the frequency of anti-nuclear antibodies (ANAs), anti-dsDNA, and anti-extractable nuclear antigen (ENA) antibodies in juvenile systemic lupus erythematosus (JSLE) patients and their association with different clinical manifestations and disease activity.

Patients And Methods: A cross-sectional study that includes 100 JSLE patients from Ain Shams University Hospital was conducted. All subjects underwent history taking, clinical examination, assessment of disease activity based on the SLE disease activity index (SLEDAI), laboratory investigations, and tests for autoantibodies, namely ANA, anti-dsDNA, and anti-ENA antibodies, including anti-Ro (SSA), anti-La (SSB), anti-Smith (Sm), and anti-U1-ribonucleoprotein (U1-RNP). Read More

View Article and Full-Text PDF

De novo lupus-like glomerulonephritis after pediatric non-kidney organ transplantation.

Pediatr Nephrol 2021 Jul 22. Epub 2021 Jul 22.

Department of Pediatrics, Division of Nephrology, University of California Los Angeles Medical Center, Los Angeles, CA, USA.

Background: We propose a novel clinically significant finding, de novo lupus-like glomerulonephritis (DNLLGN), in patients with autoantibodies and kidney abnormalities in pediatric liver transplant (LT) and intestinal inclusive transplants (ITx).

Methods: We describe the clinical, serologic, and histopathologic presentation and kidney outcomes in eight patients from our center found to have DNLLGN on kidney biopsy.

Results: Pediatric recipients of non-kidney solid organ transplants developed an unusual de novo immune complex glomerulonephritis with morphologic similarity to lupus nephritis. Read More

View Article and Full-Text PDF

Total Glucosides of Paeony Ameliorate Pristane-Induced Lupus Nephritis by Inducing PD-1 ligands Macrophages Activating IL-4/STAT6/PD-L2 Signaling.

Front Immunol 2021 5;12:683249. Epub 2021 Jul 5.

Section of Immunology & Joint Immunology Program, Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, China.

Macrophages, a major subset of innate immune cells, are main infiltrating cells in the kidney in lupus nephritis. Macrophages with different phenotypes exert diverse or even opposite effects on the development of lupus nephritis. Substantial evidence has shown that macrophage M2 polarization is beneficial to individuals with chronic kidney disease. Read More

View Article and Full-Text PDF



J Cell Biochem 2021 Jul 19. Epub 2021 Jul 19.

Retraction: "Upregulated microRNA-485 suppresses apoptosis of renal tubular epithelial cells in mice with lupus nephritis via regulating the TGF-β-MAPK signaling pathway by inhibiting RhoA expression," by Yu Tian, Yu-Xiang Han, Hui-Fang Guo, Hong-Tao Jin, Chao Sun, Xuan Qi, Li-Yan Ma, Shi-Wei Bo, J Cell Biochem. 2018; 9154-9167: The above article, published online on 26 August 2018 in Wiley Online Library (https://onlinelibrary.wiley. Read More

View Article and Full-Text PDF

Lupus retinopathy: epidemiology and risk factors.

Arq Bras Oftalmol 2021 Jul-Aug;84(4):395-401

Ophthalmology Department, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

Lupus retinopathy is a clinical manifestation of systemic lupus erythematosus in the visual system. It is generally asymptomatic; however, it can become a threatening condition. It is closely associated with the inflammatory activity and higher mortality of systemic lupus erythematosus. Read More

View Article and Full-Text PDF
December 2019

Altered expression of genes controlling metabolism characterizes the tissue response to immune injury in lupus.

Sci Rep 2021 Jul 20;11(1):14789. Epub 2021 Jul 20.

AMPEL BioSolutions, LLC and RILITE Research Institute, Charlottesville, VA, USA.

To compare lupus pathogenesis in disparate tissues, we analyzed gene expression profiles of human discoid lupus erythematosus (DLE) and lupus nephritis (LN). We found common increases in myeloid cell-defining gene sets and decreases in genes controlling glucose and lipid metabolism in lupus-affected skin and kidney. Regression models in DLE indicated increased glycolysis was correlated with keratinocyte, endothelial, and inflammatory cell transcripts, and decreased tricarboxylic (TCA) cycle genes were correlated with the keratinocyte signature. Read More

View Article and Full-Text PDF

The relationship between the modified National Institute of Health activity and chronicity scoring system, and the long-term prognosis for lupus nephritis: A retrospective single-center study.

Lupus 2021 Jul 20:9612033211034234. Epub 2021 Jul 20.

Department of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Japan.

Background: The revision of International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification guidelines for lupus nephritis (LN) was suggested by a working group, who recommended a modified National Institute of Health (NIH) activity and chronicity scoring system to evaluate active and chronic LN lesions. However, whether this approach was useful for estimating long-term prognosis for LN patients is unclear.

Methods: We conducted a retrospective cohort study in Japanese subjects with biopsy-proven LN, between 1977 and 2018. Read More

View Article and Full-Text PDF

Expression characteristics of interferon-stimulated genes and possible regulatory mechanisms in lupus patients using transcriptomics analyses.

EBioMedicine 2021 Jul 17;70:103477. Epub 2021 Jul 17.

Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, State Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, 28 Fuxing Road, Haidian District, Beijing 100853, China. Electronic address:

Background: Type I interferon signature is one of the most important features of systemic lupus erythematosus (SLE), which indicates an active immune response to antigen invasion. Characteristics of type I interferon-stimulated genes (ISGs) in SLE patients have not been well described thus far.

Methods: We analyzed 35,842 cells of PBMC single-cell RNA sequencing data of five SLE patients and three healthy controls. Read More

View Article and Full-Text PDF

How cyclosporin reduces mycophenolic acid exposure by 40% while other calcineurin inhibitors do not.

Teun van Gelder

Kidney Int 2021 Jul 17. Epub 2021 Jul 17.

Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands Albinusdreef 2 2333 ZA Leiden The Netherlands.

The most frequently used immunosuppressive treatment in kidney transplant recipients is the combination therapy of a calcineurin inhibitor and mycophenolate mofetil (MMF), with or without corticosteroids. Cyclosporin and tacrolimus are the two calcineurin inhibitors registered for this indication. Also in the treatment of glomerular diseases calcineurin inhibitors and mycophenolic acid are being used on a worldwide scale, either alone or as combined treatment. Read More

View Article and Full-Text PDF